iZafe Group (publ.) hereby announces that the wholly owned subsidiary Pilloxa AB has signed an agreement with Chiesi GmbH, the German affiliate of Chiesi Farmaceutici S.p.A., an internationally operating pharmaceutical company with a dedicated business unit for rare diseases (Chiesi Global Rare Diseases) to digitally support patients with the disease nephropathic cystinosis in Germany in their treatment journey. Goal of this initiative is to provide support to patients in dealing with their disease’s burden as well as giving a potential aid in gaining independence in daily life and hereby facilitate the transition into adolescence. Furthermore, hope is that by using the app patients will be empowered to a better tracking of their adherence and thus a better overview of their own treatment as well as a facilitation in their challenges in daily life. The collaboration is scheduled to run until 31st December 2025 and will be remunerated by Chiesi with a total of € 90,000 during the term. Over this time Pilloxa will – for better understanding patient’s needs and decision making – provide randomized and anonymized reports on the adherence to Chiesi and publish health educational information on the disease and its management provided by Chiesi in order to support the users in the daily challenges they face. Pilloxa's app itself is free of charge for patients in Germany.
"It will be a lot of fun to work with such an innovative and fast-moving company as Chiesi, even in one of Europe's largest markets. This is an excellent market to demonstrate the value of Pilloxa's solution, and as Pilloxa's business model is based on recurring revenue for each country and therapeutic area, we look forward to broadening our collaboration to more areas and countries together with Chiesi" Says Helena Rönnqvist CMO iZafe Group & BUM Pillbox
About Nephropathic cystinosis
Nephropathic cystinosis is an ultra-rare, multisystemic genetic disorder characterized by the accumulation of the amino acid cystine in the lysosomes within the cells. This accumulation leads to damage in various body tissues and organs, including kidneys, eyes, muscles, liver, pancreas and brain (1). The continuous progression of the disease, together with the high medication burden, places great demands on the patients and their caregivers. Most younger patients under 11 years of age follow the prescription correctly. (2) However, as with other chronic diseases, many teenagers and young adults with nephropathic cystinosis struggle to follow the treatment regimen. Strategies such as better information on the disease, patient self-care promotion, and facilitated transition to adult healthcare services have been suggested to improve compliance and the clinical management of cystinosis. (2)
To learn more about nephropathic cystinosis, please see https://rarediseases.org/rare-diseases/cystinosis/
About Chiesi Global Rare Diseases
Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system. For more information visit www.chiesirarediseases.com.
About Chiesi Group
Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.
By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we’re part of a global community of businesses that meet high standards of social and environmental impact. The company aims at becoming net-zero by 2035.
With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 30 countries, and counts more than 6,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.
For further information please visit www.chiesi.com.
Pilloxa is a Swedish company that works to develop apps for patients to support them in adherence to their treatment and to connect patients, healthcare providers and the pharmaceutical industry. The company provides a SaaS platform where pharmaceutical companies and other customers can design digital patient support quickly, securely and at a low cost. Connected aids such as Pilloxa's self-developed smart medication dose can also be connected to the service to support patients in taking the correct medication. Customers and partners include pharmaceutical companies such as Bayer Nordics and the Nordic office of Chiesi Global Rare Diseases, university hospitals such as the University Hospital in Oslo and universities such as the University of Gothenburg.
- Elmonem et al. Orphanet Journal of Rare Diseases (2016) 11:47
- Ariceta et al. Nephrol Dial Transplant (2015) 30: 475–480